{"nctId":"NCT02251938","briefTitle":"A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program","startDateStruct":{"date":"2014-09-29","type":"ACTUAL"},"conditions":["Non-Infectious Uveitis of the Posterior Segment of the Eye"],"count":60,"armGroups":[{"label":"DE-109 Sirolimus","type":"EXPERIMENTAL","interventionNames":["Drug: DE-109 440 μg"]}],"interventions":[{"name":"DE-109 440 μg","otherNames":["Sirolimus"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Participated in the SAKURA study\n2. Received clinical benefit from treatment in the SAKURA study\n3. Ability to sign informed consent and attend all study visits\n\nExclusion Criteria:\n\n1. Uveitis of infectious etiology\n2. Implanted device\n3. Suspected or confirmed central nervous system or ocular lymphoma\n4. Uncontrolled glaucoma\n5. Significant ocular disease\n6. Intravitreal injections in the past 60 days\n7. Intraocular surgery or treatment\n8. Ocular or periocular infection\n9. History of herpetic infection\n10. Toxoplasmosis or toxoplasmosis scar\n11. Ocular malignancy\n12. Vitrectomy\n13. Allergy or hypersensitivity to study drug\n14. Participation in other uveitis device clinical trials within 30 days\n15. Any recent systemic condition/infection\n16. Immunosuppressive therapy or immunocomprimised\n17. Cytomegalovirus infection\n18. Malignancy in remission\n19. Females who are pregnant or lactating and who are not using adequate contraceptive\n20. Medical marijuana or illegal drug use\n21. Systemic saroidosis\n22. Therapeutic radiation to the head or neck","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 in the Study Eye","description":"Best Corrected Visual Acuity (BCVA) measures the acuteness or clearness of best-corrected vision in ETDRS (Early Treatment of Diabetic Retinopathy Study) letters. An increase in BCVA indicates improvement in the best-corrected vision. A BCVA score of 85 ETDRS letters is equivalent to 20/20 vision, which is considered normal vision.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"11.35"}]}]}]},{"type":"PRIMARY","title":"Mean Change From Baseline in Intraocular Pressure at Month 12 in the Study Eye","description":"Intraocular pressure (IOP), the fluid pressure inside the eye, was measured by applanation tonometry in millimeters mercury (mmHg) with one decimal point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"4.16"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With a Shift in Choroid Status at Month 12 in the Study Eye.","description":"Ophthalmoscopy findings were reported as normal or abnormal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Changes From Baseline in Vitreous Haze (VH) Scores at Month 12","description":"Vitreous Haze (VH) scores were measured using the modified Standardized Uveitis Nomenclature Photographic Scale (SUN) :\n\n0 No inflammation\n\n0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)\n\n1. Mild blurring of the retinal vessels and optic nerve\n\n   1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+\n2. Moderate blurring of the optic nerve head\n3. Marked blurring of the optic nerve head\n4. Optic Nerve head not visible","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.09","spread":"0.847"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Receive Rescue Therapy.","description":"Rescue therapy was defined as any treatment that would have a therapeutic effect on the uveitis in the posterior segment (e.g., systemic treatment with an immunosuppressant agent, or a corticosteroid injection in the study eye) other than intravitreal DE-109 determined by the Investigator.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With a Shift in Macula Status at Month 12 in the Study Eye.","description":"Ophthalmoscopy findings were reported as normal or abnormal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With a Shift in Optic Nerve Status at Month 12 in the Study Eye.","description":"Ophthalmoscopy findings were reported as normal or abnormal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With a Shift in Retina Status at Month 12 in the Study Eye.","description":"Ophthalmoscopy findings were reported as normal or abnormal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":60},"commonTop":["Uveitis","Intraocular Pressure Increased","Cystoid Macular Oedema","Intermediate Uvei","Iridocyclitis"]}}}